NeuroPace, Inc.
US ˙ NasdaqGM ˙ US6412881053

SecurityNPCE / NeuroPace, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership2,489,391 shares
Ownership 8.30%
Morgan Stanley ownership in NPCE / NeuroPace, Inc.

2025-02-04 - Morgan Stanley has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,489,391 shares of NeuroPace, Inc. (US:NPCE). This represents 8.3 percent ownership of the company. In their previous filing dated 2024-02-09 , Morgan Stanley had reported owning 2,460,716 shares, indicating an increase of 1.17 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-02-04 2025-02-04 13G/A 2,460,716 2,489,391 1.17 8.30 -11.70
2024-02-09 2024-02-09 13G/A 2,188,593 2,460,716 12.43 9.40 6.82
2023-02-10 2023-02-10 13G 2,188,593 8.80

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROPACE COM 641288105 2,566,839 19,055 0.75 33,754 -14.20 0.0020
2026-05-27 2025-12-31 13F/A-1 NEUROPACE COM 641288105 2,547,784 1,576 0.06 39,338 49.85 0.0023
2026-02-13 2025-12-31 13F NEUROPACE COM 641288105 2,547,784 1,576 39,338 0.0023
2026-05-27 2025-09-30 13F/A-1 NEUROPACE COM 641288105 2,546,208 -38,865 -1.50 26,251 -8.84 0.0016
2025-11-14 2025-09-30 13F NEUROPACE COM 641288105 2,546,208 -38,865 26,251 0.0016
2025-08-15 2025-06-30 13F NEUROPACE COM 641288105 2,585,073 54,453 2.15 28,798 -7.41 0.0019
2025-05-15 2025-03-31 13F NEUROPACE COM 641288105 2,530,620 38,790 1.56 31,101 11.54 0.0022
2025-05-15 2024-12-31 13F/A-1 NEUROPACE COM 641288105 2,491,830 -2,511 -0.10 27,884 60.39 0.0020
2025-02-14 2024-12-31 13F NEUROPACE COM 641288105 2,491,830 -2,511 27,884 0.0020
2025-05-14 2024-09-30 13F/A-2 NEUROPACE COM 641288105 2,494,341 23,199 0.94 17,386 -6.94 0.0013
2025-02-14 2024-09-30 13F/A-1 NEUROPACE COM 641288105 2,494,341 23,199 17,386 0.0013
2024-11-14 2024-09-30 13F NEUROPACE COM 641288105 2,494,341 23,199 17,386 0.0001
2025-05-14 2024-06-30 13F/A-2 NEUROPACE COM 641288105 2,471,142 -12,841 -0.52 18,682 -43.02 0.0014
2024-10-17 2024-06-30 13F/A-1 NEUROPACE COM 641288105 2,471,142 -12,841 18,682 0.0014
2024-08-14 2024-06-30 13F NEUROPACE COM 641288105 2,471,142 -12,841 18,682 0.0014
2024-10-17 2024-03-31 13F/A-2 NEUROPACE COM 641288105 2,483,983 23,267 0.95 32,789 29.24 0.0026
2024-08-16 2024-03-31 13F/A-1 NEUROPACE COM 641288105 2,483,983 23,267 32,789 0.0003
2024-05-15 2024-03-31 13F NEUROPACE COM 641288105 2,483,983 23,267 32,789 0.0026
2024-08-16 2023-12-31 13F/A-1 NEUROPACE COM 641288105 2,460,716 61,000 2.54 25,370 8.65 0.0022
2024-02-13 2023-12-31 13F NEUROPACE COM 641288105 2,460,716 61,000 25,370 0.0022
2023-11-15 2023-09-30 13F NEUROPACE COM 641288105 2,399,716 40,850 1.73 23,349 120.46 0.0024
2023-08-14 2023-06-30 13F NEUROPACE COM 641288105 2,358,866 100,850 4.47 10,591 1.09 0.0010
2023-05-15 2023-03-31 13F NEUROPACE COM 641288105 2,258,016 69,423 3.17 10,477 221.28 0.0011
2023-02-14 2022-12-31 13F NEUROPACE COM 641288105 2,188,593 64,990 3.06 3,261 -59.05 0.0004
2022-11-14 2022-09-30 13F NEUROPACE COM 641288105 2,123,603 138,414 6.97 7,963 -18.96 0.0011
2022-10-27 2022-06-30 13F/A-1 NEUROPACE COM 641288105 1,985,189 949,405 91.66 9,826 15.55 0.0013
2022-08-15 2022-06-30 13F NEUROPACE COM 641288105 1,985,189 949,405 9,826 0.0003
2022-10-27 2022-03-31 13F/A-1 NEUROPACE COM 641288105 1,035,784 769,556 289.06 8,504 216.84 0.0011
2022-05-13 2022-03-31 13F NEUROPACE COM 641288105 1,035,784 769,556 8,504 0.0011
2022-02-14 2021-12-31 13F NEUROPACE COM 641288105 266,228 258,570 3,376.47 2,684 2,118.18 0.0003
2021-11-15 2021-09-30 13F NEUROPACE COM 641288105 7,658 66 0.87 121 -33.15 0.0000
2021-08-23 2021-06-30 13F/A-1 NEUROPACE COM 641288105 7,592 7,592 181 0.0000
2021-08-16 2021-06-30 13F NEUROPACE COM 641288105 7,592 7,592 181 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.